Allarity Therapeutics

01/05/2023

https://www.linkedin.com/company/allaritytx

17/04/2023

We're excited to share that our CEO James G. Cullem was recently interviewed by Senior Biotechnology Analyst John Vandermosten, organized by the team at Unboxing Biotech. We're grateful for the opportunity to engage in these valuable conversations with an industry professional like John.

Allarity Therapeutics (ALLR) begins its stenoparib and dovitinib trial, aligning the company's strategy towards combination therapies and providing additiona...

17/04/2023

Allarity Therapeutics (ALLR) begins its stenoparib and dovitinib trial, aligning the company's strategy towards combination therapies and providing additiona...

11/04/2023

We are pleased to be a part of this year, and to present full data on our DRP companion diagnostic. Stay tuned for more details on our findings!

FOR IMMEDIATE RELEASE Abstract Evaluating Allarity’s DRP ® Companion Diagnostic for Cisplatin Accepted at 2023 ASCO Annual Meeting Poster presentation focused on a Phase 2 Clinical Study Evaluating the Utility of a DRP ® Companion Diagnostic for Cisplatin Response in Certain Breast Cancer Patien...

28/03/2023

We are pleased to announce an update on our IXEMPRA and stenoparib Phase 2 monotherapy clinical studies:

“Patient recruitment in oncology clinical trials is an ongoing challenge and has delayed target date readouts across our sector. I am optimistic that our ongoing efforts to address this challenge will make a positive impact on our goal of providing interim data readouts in our ongoing Phase 2 studies by year’s end,” said James G. Cullem, Chief Executive Officer of Allarity Therapeutics. “Similarly, our trial protocol amendments reflect Allarity’s adaptability and commitment to seek optimal patient benefit in our clinical studies, guided by our unique DRP companion diagnostics, to select and treat most likely-to-respond patients.”

Full press release: http://bit.ly/40YTHzR

24/03/2023

Drug Development & Delivery just covered our recent milestone - the dosing of the first patient in our new combination study. Check out their article here:

Allarity Therapeutics, Inc. recently announced it has dosed the first patient in a Phase 1b clinical study evaluating the combination of stenoparib and

20/03/2023

Here’s the take of Benzinga and Precision Oncology News on the news we published this morning on our first-dosed patient in the new combination trial:

https://www.benzinga.com/news/23/03/31421911/why-allarity-therapeutics-shares-are-soaring

https://www.precisiononcologynews.com/drug-discovery-development/allarity-therapeutics-begins-phase-i-trial-dovitinib-stenoparib-combo #.ZBizvXbMJmN

Allarity Therapeutics Inc (NASDAQ: ALLR) shares are trading higher on abnormally high volume Monday after the company said it dosed the first patient in its trial studying

20/03/2023

We have just dosed the first patient in our Phase 1b clinical trial evaluating the combination of stenoparib and dovitinib to treat advanced solid tumors.
Full press release: http://bit.ly/40f6T2Q

17/10/2022

The team at Benzinga has taken a look at our DRP® and written this piece on how it positions Allarity in the oncology precision medicine space: https://bit.ly/3CEFFIT

07/10/2022

Here is the third of three excerpts from Allarity's presentation at
Ladenburg Thalmann Asset Management's Healthcare Conference last week.

One minute on upcoming milestones.

Recording of the full presentation: https://bit.ly/3V6Ge6A

06/10/2022

Here is the 2nd of 3 excerpts from Allarity's presentation at
Ladenburg Thalmann Asset Management's Healthcare Conference last week.
1 min on our pipeline asset

Full recording: https://bit.ly/3V6Ge6A

05/10/2022

Last week Allarity presented at Ladenburg Thalmann Asset Management's Healthcare Conference. Here is 1 of 3 excerpts,
1 min on Allarity's DRP (Drug Response Predictor).

Full recording: https://bit.ly/3V6Ge6A

26/09/2022

Today, we welcome Jerry McLaughlin to the Board of Directors of Allarity Therapeutics. He says in the announcement we just released:

“I firmly believe Allarity Therapeutics is in a unique position to become a leader within the personalized medicine space by developing novel combination oncology therapies together with the Company’s unique DRP® companion diagnostics. Allarity’s recent strategic shift is aligned with the ongoing patient and market realities in oncology, as we continue to see substantially higher patient benefits with combination therapies. I look forward to supporting the CEO, Jim Cullem, and the rest of the Allarity team in unlocking both the clinical and commercial potential of this strategy.”

Mr. McLaughlin is currently serving as CEO and Board Member of Life Biosciences.

Full press release: https://bit.ly/3dDOIBD

23/09/2022

Congratulation to the Oncoheroes Biosciences team for this outstanding achievement, being granted a Rare Pediatric Disease Designation by the U.S. Food and Drug Administration. We look forward to the continued partnership! The licensing agreement that covers Oncoheroes' pediatric clinical development of dovitinib was first announced in 2021: https://bit.ly/3xNJxWi

📣 BIG NEWS! We celebrate Childhood Cancer Awareness Month by announcing that the FDA has granted Rare Pediatric Disease Designation (RPDD) to dovitinib, an investigational treatment for osteosarcoma under development at Oncoheroes Biosciences.

“This is an acknowledgment of the urgent need for better treatments for children and adolescents with osteosarcoma. We hope this fantastic news can speed up the drug’s clinical development process,” stated Ricardo Garcia, Oncoheroes’ Co-Founder, and CEO.

Learn more https://oncoheroes.com/press-releases-content/2022/9/22/fda-grants-rare-pediatric-disease-designation-rpdd-to-dovitinib-for-osteosarcoma

16/09/2022

Allarity will present at Ladenburg Thalmann Asset Management's health care conference later this month. If you can't go, you can view the presentation online here: http://bit.ly/3qDK5Kt

Press release with more info: https://bit.ly/3RSRjq0

13/09/2022

Today, Zacks Investment Research initiated coverage on Allarity with a target price of $5.00 per share. Click to read the full coverage: https://bit.ly/3RWzA0z

17/08/2022

Listen to this conversation https://bit.ly/3A74yM2 between our CSO Steen Knudsen and John Vandermosten of Unboxing Biotech to learn how Allarity's approach to precision medicine, using our unique DRP (Drug Response Predictor), is different from using single-gene biomarkers.

15/08/2022

Our CEO James G. Cullem recently introduced investors to our company on Unboxing Biotech’s YouTube channel, one out of a total of four such introduction videos. Watch it for a short introduction to Allarity: https://www.youtube.com/watch?v=3BMJTO5mgcE

Allarity Therapeutics' (NASDAQ: ALLR) CEO Jim Cullem provides a short introduction to the company highlighting its combination therapy approach using its Dru...

11/08/2022

Would you like to know more about our recently refocused strategy? Biotech analyst John Vandermosten recently interviewed our CEO James G. Cullem on that very topic in one out of a total of four interviews: https://www.youtube.com/watch?v=3BMJTO5mgcE

Based on the interviews, John also wrote an article on our company, which he just shared on LinkedIn: https://www.linkedin.com/posts/john-vandermosten-8659b72_allarity-therapeutics-nasdaq-allr-diamond-activity-6963550808189657089-NxvJ?utm_source=linkedin_share&utm_medium=member_desktop_web

Allarity Therapeutics' (NASDAQ: ALLR) CEO Jim Cullem provides a short introduction to the company highlighting its combination therapy approach using its Dru...

02/08/2022

“New therapeutic development is recognized as a very challenging endeavor, with constantly shifting regulatory requirements, standard-of-care improvements as new drugs come to market, and financial and market challenges. It has therefore become increasingly difficult to advance development of monotherapies in increasingly competitive therapeutic spaces. I am confident that our strategic shift of focus and resources is the correct path forward for Allarity given the current regulatory and market realities, and will best leverage our DRP® companion diagnostics to match the right patients to the cancer therapeutic from which they will most likely benefit.” - James G. Cullem, CEO, Allarity

Full press release: https://bit.ly/3QeuQTa

Image: molecular models of dovitinib (left), stenoparib (center), and IXEMPRA® (right)

11/07/2022

Today, we have welcomed three new members to the Board of Directors of Allarity Therapeutics:

- David A. Roth, independent board member
- James G. Cullem, CEO
- Thomas Jensen, SVP

Find out more: https://bit.ly/3yVAPpX

29/06/2022

We have just announced that our Board of Directors has appointed James G. Cullem, J.D. , to Interim Chief Executive Officer and Joan Y. Brown, CPA, to Interim Chief Financial Officer.

Full press release: https://bit.ly/3y1QkuR

15/06/2022

Today, we have welcomed the distinguished oncologist Roberto Pili, M.D. to our Scientific Advisory Board. Dr. Pili is a highly respected oncologist who brings to Allarity deep expertise in renal cancers and the development of targeted therapies for personalized medicine. Read more about Dr. Pili here: https://bit.ly/3OfBpE2

27/05/2022

Today, Ladenburg Thalmann initiated coverage on Allarity with a buy rating. Click to read the full coverage on our Analyst Coverage page: https://bit.ly/3wPXCT7

15/03/2022

We have just published that Allarity has requested a Type C meeting with the U.S. Food and Drug Administration to discuss potential clinical paths to support approval of dovitinib. Press release: https://bit.ly/3ib42UF

Image: molecular model of dovitinib

05/01/2022

We look forward to participating in LifeSci Advisors' 11th Annual LifeSci Partners Corporate Access Event over the coming days, including the one-on-one investor meetings set up by the LifeSci team: https://www.linkedin.com/events/11thannuallifescipartnerscorpor6861294494344605696/

03/01/2022

We are pleased to announce that we have signed agreements with
Oncoheroes Biosciences regarding the pediatric development of dovitinib and stenoparib. Oncoheroes will acquire exclusive, global development rights to Allarity’s therapeutic candidates dovitinib, a pan-targeted kinase inhibitor (pan-TKI), and stenoparib, a PARP inhibitor and assume responsibility for their further clinical development in pediatric cancers:

Press release Oncoheroes will fund and advance the clinical development of both dovitinib and stenoparib in pediatric cancers , utilizing Allarity’s DRP® companion diagnostics Allarity has submitted a new drug application ( NDA ) for the U.S. approval of dovitinib in renal cell carcinoma ( RCC ) ...

22/12/2021

Today we announced the submission of a new drug application (NDA) with the U.S. Food and Drug Administration seeking marketing approval for dovitinib for the third-line treatment of renal cell carcinoma (RCC) patients. The filing is supported by our prior PMA submission for the use of the Dovitinib-DRP®, Allarity’s validated companion diagnostic for the drug.

Press release: https://bit.ly/3pi3CjI

Image: a molecular model of dovitinib

11/12/2021

We have just announced the outcome of the share swap offer. More than 94 % of the company’s shareholders have accepted the offer. This result has made the Board of Directors decide to apply for the delisting of Allarity Therapeutics A/S from Nasdaq First North. This delisting does not influence the first day of trading for Allarity Therapeutics, Inc. on U.S. Nasdaq, scheduled for December 21.

Press release Hørsholm, Denmark (December 11, 2021) — Allarity Therapeutics A/S (“Allarity A/S” or the “Company”) today announced that in excess of 94 % of the Company’s shareholders have accepted the Share Swap Offer, announced on November 24 and expired on December 9, pending final re...

09/12/2021

In this editorial the Chief Editor of Outsourced Pharma, asks our CEO Steve Carchedi how Allarity were able to land capacity at Lonza, an established CDMO when other emerging biotech companies encounter limited CDMO interest:

I hope you’ll agree we’ve been an honest broker when it comes to recording the frustrations emerging (and mid-sized) biopharmas have when trying to land capacity at established CDMOs. But there’s some good news of late: The tide could be turning.

25/11/2021

We have announced the initiation of the offer period, allowing shareholders in our company to swap their shares in Allarity Therapeutics A/S to shares in Allarity Therapeutics, Inc., to be listed on US Nasdaq on December 21. Read more about the details here: https://bit.ly/3CQC74g

Press release Hørsholm, Denmark (November 24, 2021) — Allarity Therapeutics A/S (“Allarity A/S” or the “Company”) hereby announces a voluntary offer and offer document to the shareholders of Allarity A/S to acquire all shares in Allarity A/S (the “Offer”), with the intent of completin...

11/11/2021

We are pleased to announce that our oral PARP inhibitor, stenoparib, has demonstrated pre-clinical antiviral activity against the delta variant of Coronavirus.
Read more: https://bit.ly/3HencEm

Image: molecular model of stenoparib

05/11/2021

We are pleased to announce that Form 424B3 has been filed by Allarity Therapeutics, Inc. Read more in the press release here: https://bit.ly/3mO5bVg

Also, in two weeks, Allarity Therapeutics A/S will convene an Extraordinary General Meeting. Find the convening notice here: https://bit.ly/3kaNJso

Image: from the Allarity labs in Denmark